window.pageData = {"stock":{"_id":3000000019126,"stockCode":"019126","masterFundShortName":"华泰柏瑞港股通医疗精选混合发起式A/C","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19126,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华泰柏瑞港股通医疗精选混合发起式A","name":"华泰柏瑞港股通医疗精选混合型发起式证券投资基金","pinyin":"htbrggtyljxhhxfqszqtzjj","fundCollectionId":4000050440000,"setUpAssetScale":12798581.26,"setUpDate":"2025-06-17T16:00:00.000Z","setUpShares":12798581.26,"inceptionDate":"2025-06-19T16:00:00.000Z","followedNum":1,"fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50440000","tickerId":50440000,"name":"华泰柏瑞基金管理有限公司"},"managers":[{"name":"张弘","stockType":"fund_manager","stockCode":"8801622136","exchange":"fm","tickerId":2608198050}],"hotMetrics":{"fss":{"stockId":3000000019126,"type":"fss","last_data_date":"2025-12-30T16:00:00.000Z","f_ins_h_s_r":0.805,"f_ind_h_s_r":0.195,"f_h_a":1033,"f_ind_h_s_r_c_hy":-0.0812,"f_ins_h_s_r_c_hy":0.08120000000000005},"fpr":{"stockId":3000000019126,"type":"fpr","f_cagr_p_r_fs_ssc":9068,"f_cagr_p_r_fs_ssrp":0.32425278482408737,"f_p_r_m1_ssc":9164,"f_p_r_m1_ssrp":0.11579177125395612,"f_p_r_m3_ssc":9022,"f_p_r_m3_ssrp":0.8427003658131028,"f_p_r_m6_ssc":8759,"f_p_r_m6_ssrp":0.9319479333181092,"f_p_r_fys_ssc":9010,"f_p_r_fys_ssrp":0.3772893772893773},"fp":{"stockId":3000000019126,"type":"fp","last_data_date":"2026-04-16T16:00:00.000Z","f_cagr_p_r_fs":0.09010901090109158,"f_p_r_m1":0.11840755181612939,"f_p_r_m3":-0.05010893246187331,"f_p_r_m6":-0.05365514846327357,"f_p_r_fys":0.07062174639033536},"ff":{"stockId":3000000019126,"type":"ff","f_fr_d":"2025-12-30T16:00:00.000Z","f_m_fr":0.012,"f_c_fr":0.002,"f_mac_fr":0.014},"f_nlacan":{"stockId":3000000019126,"type":"f_nlacan","f_nv_d":"2026-04-16T16:00:00.000Z","f_nv":1.09,"f_nv_cr":-0.008730447435430833},"f_as":{"stockId":3000000019126,"type":"f_as","f_tas":72492565.3637,"f_tas_d":"2025-12-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000019127,"name":"华泰柏瑞港股通医疗精选混合型发起式证券投资基金","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","status":"normal","stockCode":"019127","tickerId":19127,"shortName":"华泰柏瑞港股通医疗精选混合发起式C","currency":"CNY","__csrcFundId":15284,"exchange":"jj","masterFundFlag":null,"indexFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"lofFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"lastUpdated":"2025-06-30T07:54:17.182Z","inceptionDate":"2025-06-19T16:00:00.000Z","pinyin":"htbrggtyljxhhxfqszqtzjj","fundCollectionId":4000050440000,"followedNum":0}],"shareholdings":[{"date":"2025-12-30T16:00:00.000Z","fundId":3000000019126,"stockId":1000000000001276,"holdings":1662000,"marketCap":106957054,"netValueRatio":0.0968,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.19763513513513564,"stock":{"exchange":"hk","stockType":"company","stockCode":"01276","tickerId":1276,"name":"恒瑞医药"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000019126,"stockId":1000000000009606,"holdings":387200,"marketCap":104288526,"netValueRatio":0.0944,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.17986798679867977,"stock":{"exchange":"hk","stockType":"company","stockCode":"09606","tickerId":9606,"name":"映恩生物-B"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000019126,"stockId":1000000000001801,"holdings":1476381,"marketCap":101679134,"netValueRatio":0.0921,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.2090248962655593,"stock":{"stockCode":"01801","exchange":"hk","stockType":"company","tickerId":1801,"name":"信达生物"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000019126,"stockId":1000000000003692,"holdings":3034000,"marketCap":98872530,"netValueRatio":0.0895,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":0.000831765783572358,"stock":{"stockCode":"03692","exchange":"hk","stockType":"company","tickerId":3692,"name":"翰森制药"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000019126,"stockId":1000000000001530,"holdings":4467796,"marketCap":97576037,"netValueRatio":0.0884,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.19399999999999962,"stock":{"stockCode":"01530","exchange":"hk","stockType":"company","tickerId":1530,"name":"三生制药"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000019126,"stockId":1000000000006160,"holdings":597579,"marketCap":96776333,"netValueRatio":0.0876,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.12621832358674467,"stock":{"stockCode":"06160","exchange":"hk","stockType":"company","tickerId":6160,"name":"百济神州"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000019126,"stockId":1000000000006990,"holdings":266000,"marketCap":94228607,"netValueRatio":0.0853,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.2369649805447468,"stock":{"exchange":"hk","stockType":"company","stockCode":"06990","tickerId":6990,"name":"科伦博泰生物"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000019126,"stockId":1000000000001093,"holdings":6578602,"marketCap":50090426,"netValueRatio":0.0454,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.08408883363223207,"stock":{"stockCode":"01093","exchange":"hk","stockType":"company","tickerId":1093,"name":"石药集团"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000019126,"stockId":1000000000002096,"holdings":2928000,"marketCap":31656199,"netValueRatio":0.0287,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.04999999999999993,"stock":{"stockType":"company","exchange":"hk","stockCode":"02096","tickerId":2096,"name":"先声药业"}},{"date":"2025-12-30T16:00:00.000Z","fundId":3000000019126,"stockId":1000000000009926,"holdings":280312,"marketCap":28609724,"netValueRatio":0.0259,"declarationDate":"2026-01-21T16:00:00.000Z","quarterlyChange":-0.1997167138810193,"stock":{"stockType":"company","exchange":"hk","stockCode":"09926","tickerId":9926,"name":"康方生物"}}],"lastFsMetrics":{"latestTurnoverRate":1.43778284292685,"latestTurnoverRateDate":"2025-12-30T16:00:00.000Z"}},"list":[{"_id":"69cd678a83a905a12b88cc4d","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-03-30T16:00:00.000Z","stockId":3000000019126,"sao":"本产品目前主要投资创新药行业。我们主要抓住外资企业关注的大适应症、新技术展开选股。因此，聚焦抗肿瘤、心血管、自身免疫等领域，选择有相对成熟临床数据的公司。未来，随着更多临床数据的披露，以及更多新技术的出现，本产品还可以进一步拓展在in　vivo　cart、小核酸等领域的投资。","lastUpdated":"2026-04-01T18:44:26.661Z","mo":"越来越多的中国创新药通过授权形式进入海外药企研发管线，为2025-2027年的市值表现奠定基础。2025-2027年是创新药投资非常重要的三年窗口期，众多在2025年完成早期临床布局的品种将在2026年进入数据读出和商业化兑现阶段。中国企业在ADC、双抗等前沿领域的技术优势，恰好弥补海外药企专利悬崖后的管线缺口。2026年，in　vivo　cart和小核酸领域可能有更多临床数据披露，也可能出现重大投资机会。　　展望2026年，我们关注CXO产业系统性行情。随着创新药投融资回暖和biotech公司现金流改善，CXO企业订单质量显著提高。2025年积累的早期项目或将在2026年转化为临床CRO/CDMO收入，带动毛利率回升。中国CXO企业在成本效率、技术平台、交付能力等方面的综合优势依然显著。尽管面临外部环境不确定性，但全球医药产业链重构中，中国CXO的不可替代性反而得到强化。2026年国内创新药管线数量有望保持快速增长，有效对冲海外需求波动。2026年，我们将继续对CXO板块进行配置，同时创新药领域聚焦在已经成功授权的创新药大品种公司上。","fund":{"_id":3000000019126,"__csrcFundId":15284,"stockCode":"019126","masterFundShortName":"华泰柏瑞港股通医疗精选混合发起式A/C","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19126,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华泰柏瑞港股通医疗精选混合发起式A","lastUpdated":"2025-08-31T03:05:34.955Z","name":"华泰柏瑞港股通医疗精选混合型发起式证券投资基金","pinyin":"htbrggtyljxhhxfqszqtzjj","fundCollectionId":4000050440000,"setUpAssetScale":12798581.26,"setUpDate":"2025-06-17T16:00:00.000Z","setUpShares":12798581.26,"inceptionDate":"2025-06-19T16:00:00.000Z","followedNum":1,"managers":[{"stockCode":"8801622136","stockType":"fund_manager","exchange":"fm","tickerId":2608198050,"name":"张弘"}]},"announcement":{"linkText":"华泰柏瑞港股通医疗精选混合型发起式证券投资基金2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1462332","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed2f07fea5b3eb053599d","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-27T16:00:00.000Z","stockId":3000000019126,"sao":"今年前三季度，创新药板块积累了巨大的涨幅，当前是创新药分歧加大的阶段。从市值看，国内创新药龙头公司的市值和欧美医药企业依然有巨大差距；但是从整体创新药板块市值来看，A+H创新药板块市值正在接近合理区间。因此，我们判断未来创新药板块市值有望向确定性龙头公司集中。　　三季度，国内医药政策端延续“创新友好”基调：国家药监局进一步优化创新药审批流程，将临床急需境外新药审批周期缩短至4.5个月；医保局明确2025年谈判药品续约规则，对上市满3年的创新药采用“阶梯式降价”机制，缓解市场对定价压力的担忧。同时，三季度中国创新药license　out交易金额达89亿美元，其中ADC、双抗类项目占比超60%，海外授权成为业绩重要增量。　　三季度，我们将进一步增持ADC领域龙头企业，ADC+IO的联用有望进一步凸出中国创新药的效率优势。同时，我们判断在CXO也有结构性机会，我们将优选绑定全球大药企、订单能见度超2年的CDMO企业。","lastUpdated":"2026-03-09T14:02:24.518Z","fund":{"_id":3000000019126,"__csrcFundId":15284,"stockCode":"019126","masterFundShortName":"华泰柏瑞港股通医疗精选混合发起式A/C","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19126,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华泰柏瑞港股通医疗精选混合发起式A","lastUpdated":"2025-08-31T03:05:34.955Z","name":"华泰柏瑞港股通医疗精选混合型发起式证券投资基金","pinyin":"htbrggtyljxhhxfqszqtzjj","fundCollectionId":4000050440000,"setUpAssetScale":12798581.26,"setUpDate":"2025-06-17T16:00:00.000Z","setUpShares":12798581.26,"inceptionDate":"2025-06-19T16:00:00.000Z","followedNum":1,"managers":[{"stockCode":"8801622136","stockType":"fund_manager","exchange":"fm","tickerId":2608198050,"name":"张弘"}]},"announcement":{"linkText":"华泰柏瑞港股通医疗精选混合型发起式证券投资基金2025年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1379171","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed2f07fea5b3eb053599c","date":"2025-06-29T16:00:00.000Z","stockId":3000000019126,"sao":"今年上半年，中国创新药终于开始出圈，全市场逐渐关注并认同创新药的投资逻辑。但由于创新药行业整体的经营性现金流特点，导致大多数机构并不理解现有的创新药估值方式。　　从产业趋势看，中国创新药的国内市场已经进入快速渗透阶段。医保明确了创新的鼓励方向，商保也有逐步配合的趋势。未来几年，国内或将有大量创新药上市销售，市场规模有望继续快速增长。而中国创新药的海外逻辑也进入到早期爬坡期，越来越多的中国创新药通过授权的形式出现在海外药企的研发管线中。随着这些品种在2025-2027年的临床推进，相应公司市值有望增长。","declarationDate":"2025-08-29T16:00:00.000Z","lastUpdated":"2026-03-09T14:02:24.514Z","mo":"从技术升级来看，目前中国创新药的爆发主要集中在ADC和双抗领域；这些品种恰好可以弥补海外药企专利悬崖带来的逻辑短板。在未来的投资中，我们依然可以期待更多领域的中国创新力量。　　除了创新药，我们对中国医疗消费的未来并不悲观，当前只是需要更多时间来培育支付能力和消费市场。　　最后，希望大家在医药行业都获得收益，感谢大家的支持。","fund":{"_id":3000000019126,"__csrcFundId":15284,"stockCode":"019126","masterFundShortName":"华泰柏瑞港股通医疗精选混合发起式A/C","fundSecondLevel":"hybrid","stockType":"fund","areaCode":"cn","market":"a","tickerId":19126,"currency":"CNY","masterFundFlag":1,"status":"normal","exchange":"jj","shortName":"华泰柏瑞港股通医疗精选混合发起式A","lastUpdated":"2025-08-31T03:05:34.955Z","name":"华泰柏瑞港股通医疗精选混合型发起式证券投资基金","pinyin":"htbrggtyljxhhxfqszqtzjj","fundCollectionId":4000050440000,"setUpAssetScale":12798581.26,"setUpDate":"2025-06-17T16:00:00.000Z","setUpShares":12798581.26,"inceptionDate":"2025-06-19T16:00:00.000Z","followedNum":1,"managers":[{"stockCode":"8801622136","stockType":"fund_manager","exchange":"fm","tickerId":2608198050,"name":"张弘"}]},"announcement":{"linkText":"华泰柏瑞港股通医疗精选混合型发起式证券投资基金2025年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1350123","linkType":"PDF","source":"csrc_pdf"}}]}